Evidence map›Paper›PMID 34923085›Full record

ArticleAlcohol (Fayetteville, N.Y.)2022

Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker.

Peter S Harris, Cole R Michel, Youngho Yun, Courtney D McGinnis, Mohammed A Assiri, Ali Reza Ahmadi, Zhaoli Sun, James R Roede, Matthew A Burchill, David J Orlicky and 2 more

Open access · greenAbstract read
In one paragraph

Article in Alcohol (Fayetteville, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Alcohol-associated liver disease.The Journal of clinical investigation · 2024
    Review
  7. Epigenetic associations ofFrontiers in psychiatry · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Peter S HarrisSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Cole R MichelSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Youngho YunSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Courtney D McGinnisSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Mohammed A AssiriDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ali Reza AhmadiDepartment of Surgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
Zhaoli SunDepartment of Surgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
James R RoedeSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Matthew A BurchillDivision of Gastroenterology and Hepatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
David J OrlickyDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Rebecca L McCulloughSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Kristofer S FritzSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States. Electronic address: kristofer.fritz@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USUniversity of Montana · USJohns Hopkins University · USKing Saud University · SA

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS · 1995 to 2026
$32.6M
Clinical Resources for Alcoholic Hepatitis InvestigationsR24AA025017 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI ZHAOLI SUN · 2016 to 2026
$6.6M
Xenobiotic Biotransformation in Down SyndromeR01ES027593 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI James R Roede · 2017 to 2026
$5.1M
Oxidized LDL dependent reprogramming of the liver lymphatic endotheliumR01DK125595 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BURCHILL, MATTHEW A · 2020 to 2023
$1.7M
Ethanol Metabolism Disrupts Hepatic Thiol Redox Signaling and ControlR21AA026928 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI FRITZ, KRISTOFER S, ROEDE, JAMES R · 2018 to 2019
$423k
NCI NIH HHS P30 CA046934NIAAA NIH HHS R21 AA026928NIAAA NIH HHS R24 AA025017NIDDK NIH HHS P30 DK048520NIDDK NIH HHS R01 DK125595NIEHS NIH HHS R01 ES027593
6 · The paper itself

Abstract

Alcohol consumption remains a leading cause of liver disease worldwide, resulting in a complex array of hepatic pathologies, including steatosis, steatohepatitis, and cirrhosis. Individuals who progress to a rarer form of alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), require immediate life-saving intervention in the form of liver transplantation. Rapid onset of AH is poorly understood and the metabolic mechanisms contributing to the progression to liver failure remain undetermined. While multiple mechanisms have been identified that contribute to ALD, no cures exist and mortality from AH remains high. To identify novel pathways associated with AH, our group utilized proteomics to investigate AH-specific biomarkers in liver explant tissues. The goal of the present study was to determine changes in the proteome as well as epigenetic changes occurring in AH. Protein abundance and acetylomic analyses were performed utilizing nHPLC-MS/MS, revealing significant changes to proteins associated with metabolic and inflammatory fibrosis pathways. Here, we describe a novel hepatic and serum biomarker of AH, glycoprotein NMB (GPNMB). The anti-inflammatory protein GPNMB was significantly increased in AH explant liver and serum compared to healthy donors by 50-fold and 6.5-fold, respectively. Further, bioinformatics analyses identified an AH-dependent decrease in protein abundance across fatty acid degradation, biosynthesis of amino acids, and carbon metabolism. The greatest increases in protein abundance were observed in pathways for focal adhesion, lysosome, phagosome, and actin cytoskeleton. In contrast with the hyperacetylation observed in murine models of ALD, protein acetylation was decreased in AH compared to normal liver across fatty acid degradation, biosynthesis of amino acids, and carbon metabolism. Interestingly, immunoblot analysis found epigenetic marks were significantly increased in AH explants, including Histone H3K9 and H2BK5 acetylation. The increased acetylation of histones likely plays a role in the altered proteomic profile observed, including increases in GPNMB. Indeed, our results reveal that the AH proteome is dramatically impacted through unanticipated and unknown mechanisms. Understanding the origin and consequences of these changes will yield new mechanistic insight for ALD as well as identify novel hepatic and serum biomarkers, such as GPNMB.

Indexed as

Hepatitis, AlcoholicProteomicsAnimalsBiomarkersEye ProteinsGlycoproteinsHumansLiverMembrane GlycoproteinsMiceTandem Mass SpectrometryBiomarkersEye ProteinsGlycoproteinsGPNMB protein, humanGpnmb protein, mouseMembrane GlycoproteinsAcetylationAlcohol-associated hepatitisHistoneProteomics

Identifiers

PMID34923085
PMCPMC8919678
OpenAlexW4200304919

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.